| Publisher’s Note: Break the silos. Spark the strategy. Fierce Pharma Engage brings every key function together to move brands forward. Learn how now! |
Today’s Big NewsApr 22, 2025 |
| By Gabrielle Masson,Darren Incorvaia The National Institutes of Health is rolling out rules that block new grants for any researcher or institution advancing programs related to diversity, equity and inclusion. |
|
|
|
By James Waldron Harvard University is suing President Trump's administration over its threats to freeze billions in research funding. |
By James Waldron Roche has pledged to upgrade three R&D sites and pointed to the recent announcement of a new home for its cardiovascular, renal and metabolism R&D work as proof the Swiss pharma is investing serious money in the U.S. |
Sponsored by Fortrea Isagani (Gani) Chico, Vice President and Global Head of Oncology Therapeutic Expertise at Fortrea, shares how scientific advances, AI tools and flexible CRO models are accelerating oncology trials and improving patient outcomes. |
By Kevin Dunleavy Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. |
By Angus Liu In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer, Gilead Sciences’ Trodelvy has notched a much-needed win. |
By Noah Tong Legal experts agree the government should feel confident leaving oral arguments for a case deciding the fate of cost-free preventive services covered under the Affordable Care Act, with justices seemingly leaning toward protecting the task force. A decision is expected in June. |
By Fraiser Kansteiner Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the United States. The move comes as many drugmakers operating in the U.S. attempt to bolster domestic production ahead of potential pharmaceutical import tariffs. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
|
|---|
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
